Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM‐Inactivating Mutation. (11th February 2020)

• Record Type: Journal Article
• Authors: Zhang, Wei; Shi, Junping; Li, Rentao; Han, Zhiqiang; Li, Ling; Li, Guanghao; Yang, Bo; Yin, Qiang; Wang, Yingying; Ke, Yan; Li, Qiang
• Is Part Of: Oncologist. Volume 25:Number 5(2020)
• Page Start: 375
• Page End: 379
• Publication Date: 2020-02-11
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2019-0498
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: : Here, we report a case of postoperative recurrence of gallbladder carcinoma (GBC) in a patient who declined systemic chemotherapy. ATM S1905Ifs*25 and STK11 K262Sfs*25 mutations were detected by next‐generation sequencing. Oral administration of olaparib was initiated. One month later, the patient experienced relief of clinical symptoms, a decrease in CA19‐9 level, and a reduction in abnormal signal in the subcapsular region. The tumor response remained stable for approximately 13 months. This is the first case to demonstrate the clinical benefits of olaparib treatment in a patient with GBC harboring an ATM ‐inactivating mutation. This observation helps to better inform treatment options to enhance the care of patients with advanced GBC. Key Points : A patient with gallbladder carcinoma harboring an ATM ‐inactivating mutation responded to olaparib with a progression‐free survival of 13 months. This is the first report that demonstrates the clinical benefits of olaparib treatment in a patient with gallbladder carcinoma with an ATM ‐inactivating mutation. It also highlights the importance of next‐generation sequencing, which can provide valuable information for planning effective targeted therapies for gallbladder carcinoma. Evidence‐based decisions help determine the best choice of treatment for individualized patient care. Abstract : This case report is the first to show the clinical benefits of olaparib treatment in a patient with gallbladder carcinoma harboring an ATM‐inactivating mutation.